Egetis Therapeutics (EGTX) Q1 2025 earnings summary

Executive summary

• Achieved full European Commission approval for Emcitate in February 2025, marking transition to a commercial-stage rare disease company and the first and only approved treatment for MCT8 deficiency.

• First commercial launch of Emcitate in Germany on May 1, 2025, with pricing and reimbursement processes initiated in major EU markets.

• U.S. pivotal ReTRIACt study progressing, with NDA submission planned for 2025 and anticipated U.S. launch in 2026.

• Expansion efforts ongoing in Japan (via Fujimoto partnership), MENA/Turkey, and global Managed Access Programs, with over 230 patients in more than 25 countries.

• ETA guidelines published in July 2024 now recommend Emcitate for all MCT8 deficiency patients, supporting market access and awareness.

Financial highlights

• Q1 2025 revenues reached SEK 12.7 million, up from SEK 12.1 million year-over-year, mainly from Emcitate's Managed Access Program.

• Gross profit margin declined due to non-recurring milestone payments and new intangible R&D depreciations triggered by EU approval.

• Q1 2025 net loss after tax was SEK -62.9 million, improved from SEK -75 million in Q1 2024, mainly due to finance line revaluation.

• Cash position at end of March 2025 was SEK 273 million, up from SEK 252 million a year earlier.

• Operating cash flow for Q1 2025 was SEK -66.1 million, compared to SEK -55.4 million in Q1 2024, impacted by working capital changes.

Outlook and guidance

• European launch to expand from Germany to other EU4 countries, with reimbursement processes underway.

• U.S. NDA submission for Emcitate expected in 2025, with approval and launch targeted for 2026.

• Anticipates faster and larger sales uptake in the U.S. post-approval due to rapid reimbursement and higher pricing potential.

• Expansion plans include partnerships in Middle East, North Africa, Turkey, and Japan, and potential indication expansion into RTH-beta.

• Ongoing regulatory discussions in Japan may allow for approval without local clinical trials under new PMDA guidelines.